Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The results of antiviral therapy in patients with recurrent hepatitis C after liver
transplantation are lower than standard. Ribavirin has immune-modulating effects and seems to
be crucial to optimize viral treatment. The aim of this multicenter controlled study is to
examine the effect of Ribavirin pre-treatment preceding the combination therapy with
peginterferon plus ribavirin on the sustained virological response.